News | August 06, 2025
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Cenexi reports an EBITDA breakeven for the quarter
Vasograin Plus represents a major advancement in the treatment of migraine
This will be Aster’s fifth hospital in Bengaluru
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
NewCo’s pipeline includes five investigational medicines
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated
